Business Description
Imexpharm Corp
ISIN : VN000000IMP0
Compare
Compare
Traded in other countries / regions
IMP.Vietnam IPO Date
2006-12-04Description
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. Its products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.69 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.21 | |||||
| Interest Coverage | 33.8 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 12.47 | |||||
| Beneish M-Score | -1.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.3 | |||||
| 3-Year EBITDA Growth Rate | 12.9 | |||||
| 3-Year EPS without NRI Growth Rate | 11.3 | |||||
| 3-Year FCF Growth Rate | -82.3 | |||||
| 3-Year Book Growth Rate | 6.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.41 | |||||
| 9-Day RSI | 63.37 | |||||
| 14-Day RSI | 63.57 | |||||
| 6-1 Month Momentum % | 42.66 | |||||
| 12-1 Month Momentum % | 38.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.18 | |||||
| Quick Ratio | 1.51 | |||||
| Cash Ratio | 0.61 | |||||
| Days Inventory | 196.81 | |||||
| Days Sales Outstanding | 49.54 | |||||
| Days Payable | 23.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.06 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| 3-Year Dividend Growth Rate | 1.6 | |||||
| Forward Dividend Yield % | 1.06 | |||||
| 5-Year Yield-on-Cost % | 1.07 | |||||
| Shareholder Yield % | 1.58 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.84 | |||||
| Operating Margin % | 16.88 | |||||
| Net Margin % | 12.96 | |||||
| FCF Margin % | 0.82 | |||||
| ROE % | 13.15 | |||||
| ROA % | 10.9 | |||||
| ROIC % | 13.98 | |||||
| 3-Year ROIIC % | 43.88 | |||||
| ROC (Joel Greenblatt) % | 20.86 | |||||
| ROCE % | 17.02 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 37.14 | |||||
| Forward PE Ratio | 21.27 | |||||
| PE Ratio without NRI | 36.83 | |||||
| Shiller PE Ratio | 41.36 | |||||
| Price-to-Owner-Earnings | 109.27 | |||||
| PEG Ratio | 2.46 | |||||
| PS Ratio | 3.75 | |||||
| PB Ratio | 3.48 | |||||
| Price-to-Tangible-Book | 3.67 | |||||
| Price-to-Free-Cash-Flow | 333.94 | |||||
| Price-to-Operating-Cash-Flow | 105.23 | |||||
| EV-to-EBIT | 20.24 | |||||
| EV-to-EBITDA | 15.55 | |||||
| EV-to-Revenue | 3.39 | |||||
| EV-to-FCF | 427.06 | |||||
| Price-to-Projected-FCF | 3.67 | |||||
| Price-to-Median-PS-Value | 1.71 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.89 | |||||
| Price-to-Graham-Number | 2.45 | |||||
| Price-to-Net-Current-Asset-Value | 7.77 | |||||
| Earnings Yield (Greenblatt) % | 4.93 | |||||
| FCF Yield % | 0.24 | |||||
| Forward Rate of Return (Yacktman) % | 13.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imexpharm Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚«) | 2,083,396.003 | ||
| EPS (TTM) (â‚«) | 2531.18 | ||
| Beta | 0 | ||
| Volatility % | 29.12 | ||
| 14-Day RSI | 63.57 | ||
| 14-Day ATR (â‚«) | 2981.217017 | ||
| 20-Day SMA (â‚«) | 88845 | ||
| 12-1 Month Momentum % | 38.5 | ||
| 52-Week Range (â‚«) | 47363.636363 - 99900 | ||
| Shares Outstanding (Mil) | 77.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imexpharm Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imexpharm Corp Stock Events
| Event | Date | Price(â‚«) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imexpharm Corp Frequently Asked Questions
What is Imexpharm Corp(STC:IMP)'s stock price today?
The current price of STC:IMP is â‚«94000.00. The 52 week high of STC:IMP is â‚«99900.00 and 52 week low is â‚«47363.64.
When is next earnings date of Imexpharm Corp(STC:IMP)?
The next earnings date of Imexpharm Corp(STC:IMP) is .
Does Imexpharm Corp(STC:IMP) pay dividends? If so, how much?
The Dividend Yield %  of Imexpharm Corp(STC:IMP) is 1.06% (As of Today), Highest Dividend Payout Ratio of Imexpharm Corp(STC:IMP) was 0.68. The lowest was 0.28. And the median was 0.53. The  Forward Dividend Yield % of Imexpharm Corp(STC:IMP) is 1.06%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers